Cargando…

Immunosuppression and Chagas Disease: A Management Challenge

Immunosuppression, which has become an increasingly relevant clinical condition in the last 50 years, modifies the natural history of Trypanosoma cruzi infection in most patients with Chagas disease. The main goal in this setting is to prevent the consequences of reactivation of T. cruzi infection b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pinazo, María-Jesús, Espinosa, Gerard, Cortes-Lletget, Cristina, Posada, Elizabeth de Jesús, Aldasoro, Edelweiss, Oliveira, Inés, Muñoz, Jose, Gállego, Montserrat, Gascon, Joaquim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3547855/ https://www.ncbi.nlm.nih.gov/pubmed/23349998 http://dx.doi.org/10.1371/journal.pntd.0001965

Ejemplares similares

Altered Hypercoagulability Factors in Patients with Chronic Chagas Disease: Potential Biomarkers of Therapeutic Response
por: Pinazo, Maria-Jesus, et al.
Publicado: (2016)

Pulmonary Infiltrates and Eosinophilia in a 25-Year-Old Traveler
por: Muñoz, Jose, et al.
Publicado: (2013)

Chagas Disease among the Latin American Adult Population Attending in a Primary Care Center in Barcelona, Spain
por: Roca, Carme, et al.
Publicado: (2011)

Characterization of Digestive Involvement in Patients with Chronic T. cruzi Infection in Barcelona, Spain
por: Pinazo, María-Jesús, et al.
Publicado: (2014)

Prevalence of Chagas Disease in Latin-American Migrants Living in Europe: A Systematic Review and Meta-analysis
por: Requena-Méndez, Ana, et al.
Publicado: (2015)

Socio-Cultural Aspects of Chagas Disease: A Systematic Review of Qualitative Research
por: Ventura-Garcia, Laia, et al.
Publicado: (2013)

Plasma-Derived Extracellular Vesicles as Potential Biomarkers in Heart Transplant Patient with Chronic Chagas Disease
por: Cortes-Serra, Nuria, et al.
Publicado: (2020)

Amaryllidaceae plants: a potential natural resource for the treatment of Chagas disease
por: Martínez-Peinado, Nieves, et al.
Publicado: (2021)

Characterization of Latin American migrants at risk for Trypanosoma cruzi infection in a non-endemic setting. Insights into initial evaluation of cardiac and digestive involvement
por: Laynez-Roldán, Pedro, et al.
Publicado: (2023)

Multi-criteria decision analysis approach for strategy scale-up with application to Chagas disease management in Bolivia
por: Pinazo, Maria-Jesus, et al.
Publicado: (2021)

In silico Design of an Epitope-Based Vaccine Ensemble for Chagas Disease
por: Michel-Todó, Lucas, et al.
Publicado: (2019)

Chagas Cardiomiopathy: The Potential of Diastolic Dysfunction and Brain Natriuretic Peptide in the Early Identification of Cardiac Damage
por: Garcia-Alvarez, Ana, et al.
Publicado: (2010)

Corrigendum: In silico Design of an Epitope-Based Vaccine Ensemble for Chagas Disease
por: Michel-Todó, Lucas, et al.
Publicado: (2020)

Introducing automation to the molecular diagnosis of Trypanosoma cruzi infection: A comparative study of sample treatments, DNA extraction methods and real-time PCR assays
por: Abras, Alba, et al.
Publicado: (2018)

Biomarkers of therapeutic responses in chronic Chagas disease: state of the art and future perspectives
por: Pinazo, Maria-Jesus, et al.
Publicado: (2015)

Evaluation of a chemiluminescent enzyme-linked immunosorbent assay for the diagnosis of Trypanosoma cruzi infection in a nonendemic setting
por: Izquierdo, Luis, et al.
Publicado: (2013)

Characterization of digestive disorders of patients with chronic Chagas disease in Cochabamba, Bolivia
por: Pinto, Jimy-Jose, et al.
Publicado: (2019)

Strengthening the Bolivian pharmacovigilance system: New surveillance strategies to improve care for Chagas disease and tuberculosis
por: Cortes-Serra, Nuria, et al.
Publicado: (2020)

High prevalence of S. Stercoralis infection among patients with Chagas disease: A retrospective case-control study
por: Puerta-Alcalde, Pedro, et al.
Publicado: (2018)

A strategy for scaling up access to comprehensive care in adults with Chagas disease in endemic countries: The Bolivian Chagas Platform
por: Pinazo, Maria-Jesus, et al.
Publicado: (2017)

Development of Diagnostics for Chagas Disease: Where Should We Put Our Limited Resources?
por: Picado, Albert, et al.
Publicado: (2017)

Results and evaluation of the expansion of a model of comprehensive care for Chagas disease within the National Health System: The Bolivian Chagas network
por: Pinazo, Maria-Jesus, et al.
Publicado: (2022)

Economic crisis and increased immigrant mobility: new challenges in managing Chagas disease in Europe
por: Jackson, Yves, et al.
Publicado: (2014)

Rapid diagnostic tests duo as alternative to conventional serological assays for conclusive Chagas disease diagnosis
por: Egüez, Karina E., et al.
Publicado: (2017)

State-of-the-Art in the Drug Discovery Pathway for Chagas Disease: A Framework for Drug Development and Target Validation
por: Gabaldón-Figueira, Juan Carlos, et al.
Publicado: (2023)

Use of rapid diagnostic tests (RDTs) for conclusive diagnosis of chronic Chagas disease – field implementation in the Bolivian Chaco region
por: Lozano, Daniel, et al.
Publicado: (2019)

Extracellular Vesicles in Trypanosoma cruzi Infection: Immunomodulatory Effects and Future Perspectives as Potential Control Tools against Chagas Disease
por: Cortes-Serra, Nuria, et al.
Publicado: (2022)

Short-term follow-up of chagasic patients after benznidazole treatment using multiple serological markers
por: Fernández-Villegas, Ana, et al.
Publicado: (2011)

Health Policies to Control Chagas Disease Transmission in European Countries
por: Requena-Méndez, Ana, et al.
Publicado: (2014)

A Phase 2, Randomized, Multicenter, Placebo-Controlled, Proof-of-Concept Trial of Oral Fexinidazole in Adults With Chronic Indeterminate Chagas Disease
por: Torrico, Faustino, et al.
Publicado: (2022)

Robust and Reproducible Quantification of the Extent of Chest Radiographic Abnormalities (And It’s Free!)
por: Requena-Méndez, Ana, et al.
Publicado: (2015)

Amaryllidaceae alkaloids with anti-Trypanosoma cruzi activity
por: Martinez-Peinado, Nieves, et al.
Publicado: (2020)

WHF IASC Roadmap on Chagas Disease
por: Echeverría, Luis Eduardo, et al.
Publicado: (2020)

Always Look on the Bright Side – Lessons Learned from Another Decade of Integrating Care
por: Stein, K. Viktoria, et al.
Publicado: (2022)

Challenges and perspectives of Chagas disease: a review
por: Pereira, Paulo Câmara Marques, et al.
Publicado: (2013)

Immunosuppressants: Various infections and reactivation of Chagas disease: 2 case reports
Publicado: (2021)

COVID-19: Implications for People with Chagas Disease
por: Zaidel, Ezequiel José, et al.
Publicado: (2020)

A Branched and Double Alpha-Gal-Bearing Synthetic Neoglycoprotein as a Biomarker for Chagas Disease
por: Montoya, Alba L., et al.
Publicado: (2022)

Identification of Trypanosoma cruzi Growth Inhibitors with Activity In Vivo within a Collection of Licensed Drugs
por: Martinez-Peinado, Nieves, et al.
Publicado: (2021)

Human African Trypanosomiasis in a Spanish traveler returning from Tanzania
por: Gómez-Junyent, Joan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_mtng28q271c2oqmhvu4dlrujvb